

Original Research Article

Serotypes and Antibiotic Susceptibility of *Streptococcus pneumoniae* Isolated from Adults with Lower Respiratory Tract Infection in Jos, Nigeria

Okolo M.O^{1*}, Chuhwak E.K², Emanghe U.E³, Onyedibe K.I¹, Banwat E.B¹ and Egah D.Z¹

¹Department of Medical Microbiology and Parasitology, Jos University Teaching Hospital, Jos, Plateau State, Nigeria.

²Department of Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria.

³Department of Medical Microbiology and Parasitology, University of Calabar Teaching Hospital, Calabar, Cross River State, Nigeria.

Accepted 13th August, 2015.

Background: *Streptococcus pneumoniae* causing lower respiratory tract infection remains a global challenge, particularly when it involves drug resistant isolates. It is a cause of morbidity and mortality in developing countries including Nigeria. Several studies documented the prevalence, serologic and molecular types, antibiotic susceptibility patterns; as well as the herd effect following vaccination. This study thus determined the prevalence of the Heptavalent vaccine serotype of *Streptococcus pneumoniae* in adult patients and the antibiotic susceptibility pattern. **Methods:** A cross sectional study involving 91 adult patients with clinical features of lower respiratory tract infection were recruited for this study. Serologic typing as well as antibiotic susceptibility testing were carried out on the *Streptococcus pneumoniae* isolates. **Results:** Four (4.4%) of the 91 patients had *Streptococcus pneumoniae* isolated from their clinical samples. Only one (14.3%) of the heptavalent vaccine serotype (serotype 23F) was found. All the four *Pneumococci* were susceptible to Ceftriaxone, Levofloxacin, Trimethoprim- sulfamethoxazole and Amoxicillin-clavulanic acid but varying susceptibility to Erythromycin and Tetracycline. **Conclusion:** Heptavalent vaccine serotype of *Streptococcus pneumoniae* causes infection in adults. Early detection and appropriate antibiotic susceptibility will enhance proper management of patient. Vaccination of children will reduce infection due to the vaccine serotypes in adult population.

Keywords: *Streptococcus pneumoniae*, Heptavalent vaccine, Antibiotics, Serology.

INTRODUCTION

Streptococcus pneumoniae remains an important bacterial cause of lower respiratory tract infection responsible for, marked, morbidity and mortality in both developing and industrialized countries (Chih-Jung et al., 2007). Colonization of the nasopharynx by *Streptococcus pneumoniae* serves as an important reservoir for community-wide spread of these pathogens and a key factor preceding pneumococcal diseases (Chih-Jung et al., 2007; Pichichero and Casey, 2007).

The virulence of the organism is due to its possession of polysaccharide capsule that enables it to resist phagocytes hence evading host immune response. Based on capsular polysaccharides, the *pneumococci* are classified into at least 90 serologic types (Hausdorff et al., 2005; Chih-Jung et al., 2007; Pichichero and Casey, 2007). The prevalence and the distribution of serotypes differ significantly among isolates,

from one geographic region to the other; from asymptomatic carriers versus those from patients with invasive pneumococcal diseases³. Despite the large number of serologic types only very small numbers are implicated in infections (Hausdorff et al., 2005; Aguiar et al., 2008).

The 7-valent *pneumococcal* polysaccharide –CRM₁₉₇-protein conjugate vaccine (PCV-7) was introduced in several countries and recommended to expanded risk groups followed by the universal vaccination program. This vaccine provides protection against invasive pneumococcal infections caused by serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, and reduces nasopharyngeal carriage of these serotypes after vaccination (Black et al., 2000). In a prospective study by Lexau et al., in the United States, it was observed that mass vaccination of children resulted in a herd effect, shown by the reduction in the

*Corresponding Author: Dr. Okolo, Mark Ojogba. Department of Medical Microbiology and Parasitology, Jos University Teaching Hospital, Jos, Plateau State, Nigeria. Email: okolomarkojogba2b@yahoo.com

incidence of invasive diseases among adults. The PCV-7 includes the most resistant serotypes, with hopes that vaccination effectively controls the spread of resistant clones (Lexau et al., 2005; Stephens et al., 2005). Several other studies particularly in the United States, showed that the reduction of vaccine serotypes in asymptomatic carriage and invasive pneumococcal diseases was countered by replacement with non vaccine serotypes (Laurent et al., 2009; Miller et al., 2011; Ladhani et al., 2013).

The objectives of this study were to determine the prevalence of Hepta valent vaccine serotypes of *Streptococcus pneumoniae* in adult patients with lower respiratory tract infection, to describe the antibiotic susceptibility of all the *pneumococci*.

METHODS

This prospective study was carried out among adults with lower respiratory tract infection after written informed consents were obtained from them. Blood and sputum samples were obtained from all the patients. Three sets of blood were collected for culture. Culture of both blood and sputum from each patient was carried out. Identification of *S.pneumoniae* isolates was confirmed by optochin sensitivity and bile solubility test.

The preliminary typing using polyvalent typing sera (Debendiagnosics Ltd, United Kingdom) allowed to determine the pneumococcal isolate. Complete serotyping was performed at the National Veterinary Research Institute (VOM, Nigeria) using latex particles sensitized with antisera (monovalent typing sera) purchased from Debendiagnosics Ltd, United Kingdom. The panel of monovalent sera used allowed to determine the heptavalent vaccine serotypes (4,6B,9V,14,18C,19F and 23F). 10ul of pneumococcal overnight growth culture adjusted to 1Mc Farland turbidity standard using a nephelometer was mixed with 10ul of latex reagent on a glass slide and rocked for 10seconds. The presence of agglutination of the latex particles read with the naked eye within 10 seconds was considered as positive reaction. This procedure was carried out for every *S. pneumoniae* isolated.

The antimicrobial susceptibility testing was performed using the disc diffusion method (tetracycline, trimethoprim-sulfamethoxazole, erythromycin, levofloxacin). MIC determination was by E test method (ceftriaxone, amoxicillin-clavulanic acid, Oxoid U.K). Data were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement (CLSI, 2010).

RESULTS

Of the 91 adult patients enrolled, 4 (4.4%) had *Streptococcus pneumoniae* isolated. (Table1). Out of the four pneumococcal isolates, two were from age group 21-30years (6.7%) while age groups 31-40years and 41-50 years, both had one isolate each accounting for 4.2% and 10% respectively.

Based on the sex of the study population, three (75%) of the *S. pneumoniae* isolates were obtained from males while the remaining (25%) from a female. (Table2). Out of the four *S. pneumoniae* isolates obtained, only one (14.3%) of the heptavalent vaccine serotype was found (Fig1). All of the four *S. pneumoniae* isolates were susceptible to Ceftriaxone, Levofloxacin and Trimethoprim-sulfamethoxazole; Amoxicillin-clavulanic acid, but varying susceptibility to Erythromycin and Tetracycline. (Table4).

DISCUSSION

Results from this study showed that lower prevalence (4.4%) of streptococcal infection is seen among adult patients. Similarly, low values were reported by Agwu et al., (6.4%) in Edo State, Nigeria and 1.4% by Fashae et al., among children in Ibadan, Nigeria (Fashae et al., 2002; Agwu et al., 2006). Higher values were reported in several other studies (Adelaye et al., 2008; Po-Ren et al., 2009). The antimicrobial abuse, socioeconomic status of the study population may be possible factors implicated in the low prevalence of *Streptococcus pneumoniae* infection in this study.

In this study, *Pneumococcus* was isolated more from males (75%) than females (25%). This is similar to findings in a study by Francisco and his colleagues in Alicante, Spain (Francisco et al., 2008). The *pneumococcal* isolates were all obtained from patients in the age range 21-50years. This contradicts findings by Regev-Yochay et al, which showed high prevalence of *pneumococcal* infections at the extremes of life (Regev-Yochay et al., 2004).

By virtue of the predisposing factors to infection, the most prevalent was alcohol intake (16.5%) followed by cigarette smoking (12.1%). A reversal of this finding was observed by Francisco et al., in Spain. These differences may be due to geographic locations of the study. Alcohol abuse is known to impair muco-ciliary clearance just like cigarette smoke (Francisco et al., 2008). Cigarette smoke enhances bacterial adherence, and disrupts the respiratory tract. These factors, alone or together can explain the increased risk of pneumococcal disease in smokers. A causative role of smoking in the pathogenesis of pneumococcal infections seems highly plausible. Indeed, a case control study found an increased risk of *pneumococcal* infection among current and former smokers (Regev-Yochay et al., 2004; Francisco et al., 2008).

Based on the heptavalent vaccine serotype, only one (25%) was obtained in this study (i.e serotype 23F). This serotype is associated with invasive and non invasive *pneumococcal* infection in children, the elderly and non elderly adults. This serotype was the third common serotype in a study in Germany (Regev-Yochay et al., 2004; Aguiaret al., 2008). This difference in the serotype prevalence might be due to the differences in the age group studied, the geographic location, genetic predisposition, as well as the number of the studied population.

Report by the CNRP in 2006, confirmed a high prevalence of serotype 7F in adult population. This increase in the frequency of the serotype 7F in invasive infections among adults was described in Portugal (Regev-Yochay et al., 2004; Adelaye et al., 2008). The PCV-7 related serotypes represented 40.6 % of *S. pneumoniae* isolated from adults' invasive diseases.^{8,17,18} Laurent et al reported a higher prevalence of serotype 19A in a molecular capsular typing study in France (Crew – Brown et al., 1997; Regev – Yochay et al., 2004; Laurent et al., 2009).

Based on the susceptibility pattern of *Streptococcus pneumoniae* isolate to antibiotics, all were susceptible to Ceftriaxone, Levofloxacin, Amoxicillin-clavulanic acid and Trimethoprim- sulfamethoxazole; but varying susceptibility to Erythromycin and Tetracycline. Varying susceptibility to Erythromycin was also reported by Laurent et al in a molecular capsular typing carried out in France (Crew – Brown et al., 1997; Regev – Yochay et al., 2004; Laurent et al., 2009).

Table 1. Prevalence of *Streptococcus pneumoniae* infection among adult patients with lower respiratory tract infection in Jos, Nigeria

Age group (years)	Total no Tested	<i>S. pneumoniae</i> isolates	Percent (%)
11– 20	9	0	0
21 – 30	30	2	6.7
31 – 40	24	1	4.2
41 – 50	10	1	10
51 – 60	9	0	0
61 – 70	5	0	0
71 – 80	2	0	0
81 – 90	1	0	0
91 – 100	0	0	0
101 – 110	1	0	0
Total	91	4	4.4

$\chi^2 = 2.17$ $p = 0.975$

Table 2. Distribution of *Streptococcus pneumoniae* isolates by sex of adult patients with lower respiratory tract infection in Jos, Nigeria

Sex	<i>S. pneumoniae</i> isolates	Percent (%)
Female	1	25
Male	3	75
Total	4	100

Table 3: Distribution of some predisposing factors to *Streptococcus pneumoniae* infection among adult patients with lower respiratory tract infection in Jos, Nigeria

Sex (male)	54%
Age (years)	37.4
Cigarette smoking	12.1%
Alcohol intake	16.5%
HIV	3.3%


**Fig 1.** Distribution of Heptavalent vaccine serotype/serogroup of *Streptococcus pneumoniae* among adult patients with lower respiratory tract infection in Jos, Nigeria

Table 4. Antibiotic susceptibility pattern of *Streptococcus pneumoniae* among adult patients with lower respiratory tract infection in Jos, Nigeria

Antibiotics	%Sensitive	%Resistant
Ceftriaxone	100	0
Trimethoprim-sulfamethoxazole	100	0
Levofloxacin	100	0
Amoxicillin-clavulanic acid	100	0
Erythromycin	75	25
Tetracycline	50	50

They reported a high resistance of serotype 19A to Erythromycin and suggested that if serotype 19A would be added to a new pneumococcal vaccine (PCV) formulation, the incidence of antibiotic resistance among pneumococci would fall. It was reported that the emergence of non-vaccine serotypes has been observed in countries with low PCV-7 vaccine up take, such as Spain (Crew – Brown et al., 1997; Hicks et al., 2007; Griffin et al., 2013).

Finally the high cost of molecular investigation did not permit us to carry out a highly reliable molecular typing to compare with the conventional serotyping which is still acceptable the world over. These results confirm the presence of heptavalent vaccine serotypes as agents of disease in adults.

ACKNOWLEDGEMENTS

We wish to thank the staff of the Medical Microbiology Laboratory at the University Teaching Hospital, Jos, Nigeria and National Veterinary Research Institute, Vom, Nigeria for the assistance during the period of this study.

CONFLICT OF INTEREST

We declare no conflicts of interest.

REFERENCES

- Adelaye A, Uju L, Idikaa N, Sobande O. (2008) Cotrimoxazole resistance in *Streptococcus pneumoniae* isolated from sputum of HIV – positive patients. *West Indian Med. J.* 57(5): 497 – 499.
- Aguiar SI, Serrano I, Pinto FR, Melo-Christino J, Ramirez M (2008). Changes in *Streptococcus pneumoniae* serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. *Clin Microbiol Infect* 14:835-843.
- Agwu E, Ohinion A.A, Agba M.I (2006). Incidence of *Streptococcus pneumoniae* infections among patients attending tuberculosis clinics in Ekpoma Nigeria. *Shiraz E- Medicine J.* 7(1).
- Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Mdore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K (2000). Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children, Northern California Kaiser Permanent Vaccine Study Center Group. *Pediatr Infect Dis J.* 19:187-195.
- Chih- Jung C, Yhu-Chering H, Lin-Hui S, Tzou-Yien L (2007). Nasal carriage of *Streptococcus pneumoniae* in healthy children and adults in Northern Taiwan. *Diag Microbiol Infect Dis* 59:265-269.
- Clinical and Laboratory Standards Institute, 2010 Performance Standard for antimicrobial susceptibility testing. Disc diffusion. Twentieth supplemental testing. Document M100-S20, CLSI, Wayne, PA (2010).
- Crew – Brown HH, Karstaedt AS, Sanders GL, Khoosal M, Jones N, Klugman KP (1997). *Streptococcus pneumoniae* blood culture isolates from patients with and without human immunodeficiency, virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. *Clin Infect Dis* 25(5): 1165 – 1172.
- Fashae K.F, Ogunsola F.T, salawu O.M (2002). A possible outbreak of *Streptococcus pneumoniae* invasive infection in children in Ibadan, Nigeria. *Afri J of Med Sci.* 31(2): 141-143.
- Franciso J, Jose – Maria C, Lucio A, Silvia M, Ruth C, Victoria OT, Pablo R, Jaince M (2008). A comparative study of bacteraemic and non – bacteraemic pneumococcal pneumonia. *E J I M* 19(1): 15 – 21.
- Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG (2013). U.S hospitalizations for pneumonia after a decade of pneumococcal vaccination. *N E J M.* 369:155.
- Hausdorff WP, Feikin DR, Klugman KP (2005). Epidemiological differences among pneumococcal serotypes. *Lancet Infect Dis.* 5:83-93.
- Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG (2007). Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination;1998-2004. *J Infect Dis.* 196:1346-1354.
- Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E (2013). Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and Wales. *Clin Infect Dis.* 56: 633.
- Laurent D, Marie-Cecile P, Josette R (2009). Emergence of *Streptococcus pneumoniae* of serotypes 19A in France: molecular capsular serotyping, antimicrobial susceptibilities and epidemiology. *Diag Microbiol Infect Dis.* 65: 49-57.
- Lexau CA, Lynfield R, Danila R, Piiishvili T, Facklam R, Farley MM, Harrison LH, Scaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG (2005). Changing epidemiology of invasive pneumococcal disease among older adults in the era of paediatric pneumococcal conjugate vaccine. *JAMA* 294: 2043-2051.
- Miller E, Andrews NJ, Waight PA, Slack MP, George RC (2011). Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. *Lancet Infect Dis.* 11: 760.
- Pichichero ME, Casey JR (2007). Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. *JAMA* 298 :1772-1778.
- Po-Ren H and Kwen-Tay L (2009). Antimicrobial resistance in *Streptococcus pneumoniae*, Taiwan. *E I D.* 12: 1213-1220.
- Regev – Yochay G, Raz M, Dagan R (2004). Nasopharyngeal carriage of *Streptococcus pneumoniae* by adults and children in community and family settings. *Clin Infect Dis.* 38: 632 – 639.
- Stephens DS, Zughair SM, Whitney CG (2005). Incidence of macrolide resistance in *Streptococcus pneumoniae* after introduction of the pneumococcal conjugate vaccine population-based assessment. *Lancet.* 365:855-863.